EXPERIMENTAL IMMUNOPREVENTION OF TYPE-I DIABETES-MELLITUS

[1] Bach JF, Boitard C, Experimental models of type I diabetes, Pathol Immunopathol Res, 304, pp. 77-78, (1987)

[2] Castano L, Eisenbarth GS, Type I diabetes mellitus: a chronic autoimmune disease of human, mouse and rat, Annual Review of Immunology, pp. 647-679, (1990)

[3] Marliss EB, Nakhooda AF, Poussier P, Sima AAF, The diabetic syndrome of the “BB” Wistar rat: possible relevance to type 1 (insulin‐dependent) diabetes in man, Diabetologia, 22, pp. 225-232, (1982)

[4] Colle E, Genetic susceptibility to the development of spontaneous insulin‐dependent diabetes mellitus in the rat, Clin Immunol Immunopathol, 57, pp. 1-9, (1990)

[5] Acha-Orbea H, McDevitt HO, The first external domain of the nonobese diabetic mouse class II I‐A ß chain is unique, Proceedings of the National Academy of Sciences, 84, pp. 2435-2439, (1987)

[6] Lampeter EF, Signore A, Gale EAM, Pozzilli P, Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin‐dependent) diabetes mellitus, Diabetologia, 32, pp. 703-708, (1989)

[7] Boitard C, Pathophysiology of autoimmune disease, Klin Wochenschr, 68, 21, pp. 1-9, (1990)

[8] Schreiber SL, Chemistry and biology of the immunophilins and the immunosuppressive ligands, Science, 251, pp. 283-287, (1991)

[9] Laupacis A, Gardell C, Dupre J, Stiller CR, Keown P, Wallace AC, Cyclosporin prevents diabetes in BB Wistar rat, Lancet, 1, pp. 10-12, (1983)

[10] Stiller CR, Laupacis A, Keown PA, Gardell C, Dupre J, Thibert P, Wall W, Cyclosporin action, pharmacokinetics, and effect in the BB rat model, Metabolism, 32, pp. 69-72, (1983)

[1] Bach JF, Boitard C, Experimental models of type I diabetes, Pathol Immunopathol Res, 304, pp. 77-78, (1987)

[2] Castano L, Eisenbarth GS, Type I diabetes mellitus: a chronic autoimmune disease of human, mouse and rat, Annual Review of Immunology, pp. 647-679, (1990)

[3] Marliss EB, Nakhooda AF, Poussier P, Sima AAF, The diabetic syndrome of the “BB” Wistar rat: possible relevance to type 1 (insulin‐dependent) diabetes in man, Diabetologia, 22, pp. 225-232, (1982)

[4] Colle E, Genetic susceptibility to the development of spontaneous insulin‐dependent diabetes mellitus in the rat, Clin Immunol Immunopathol, 57, pp. 1-9, (1990)

[5] Acha-Orbea H, McDevitt HO, The first external domain of the nonobese diabetic mouse class II I‐A ß chain is unique, Proceedings of the National Academy of Sciences, 84, pp. 2435-2439, (1987)

[6] Lampeter EF, Signore A, Gale EAM, Pozzilli P, Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin‐dependent) diabetes mellitus, Diabetologia, 32, pp. 703-708, (1989)

[7] Boitard C, Pathophysiology of autoimmune disease, Klin Wochenschr, 68, 21, pp. 1-9, (1990)

[8] Schreiber SL, Chemistry and biology of the immunophilins and the immunosuppressive ligands, Science, 251, pp. 283-287, (1991)

[9] Laupacis A, Gardell C, Dupre J, Stiller CR, Keown P, Wallace AC, Cyclosporin prevents diabetes in BB Wistar rat, Lancet, 1, pp. 10-12, (1983)

[10] Stiller CR, Laupacis A, Keown PA, Gardell C, Dupre J, Thibert P, Wall W, Cyclosporin action, pharmacokinetics, and effect in the BB rat model, Metabolism, 32, pp. 69-72, (1983)